Kazakhstan and India Move to Localize Drug Production Through Strategic Pharmaceutical Business Partnerships

Kazakhstan and India meet in New Delhi to boost pharmaceutical cooperation. Discover new investment projects and the Almaty region's new production clusters.

By: AXL Media

Published: Mar 28, 2026, 6:46 AM EDT

Source: The information in this article was sourced from Trend News Agency

Strengthening Bilateral Ties in the Pharmaceutical Sector

Kazakhstan and India have entered a new phase of economic cooperation following a high level business meeting in New Delhi on March 28. The forum served as a platform for Deputy Minister of Foreign Affairs Alibek Kuantyrov and representatives from several premier Indian pharmaceutical firms, including Abaris Healthcare and Akriti Pharmaceuticals, to explore investment opportunities. The primary objective is to move beyond simple trade and toward the localization of drug and medical equipment production within Kazakh borders. This initiative is seen as a vital step in enhancing Kazakhstan’s healthcare infrastructure while providing Indian firms with a strategic gateway to the broader Central Asian market.

The Foundation of Educational and Medical Research

During the summit, Alibek Kuantyrov pointed to the significant presence of over 12,000 Indian students currently enrolled in Kazakh institutions, primarily within medical universities. This educational exchange is viewed as a foundational element for long term collaboration in healthcare and clinical research. By training future Indian medical professionals in Kazakhstan, both nations are building a human capital bridge that facilitates easier integration of medical standards and research methodologies. This synergy is expected to accelerate joint ventures in biotechnology and the development of new therapeutic treatments tailored to regional health needs.

Industrial Growth and the Almaty Regional Cluster

The Almaty region has emerged as a focal point for this international partnership, evidenced by the recent investment from India’s MSN Group. The company has committed to building a full cycle pharmaceutical plant in the area, which serves as a blueprint for future industrial engagements. Darkhan Satibaldy, the Mayor of Almaty, highlighted the city’s rapid development of modern pharmaceutical clusters and scientific centers during the forum. These facilities are designed to support the entire production chain, from initial research and development to the final manufacturing of essential medicines, thereby reducing Kazakhstan’s reliance on imported drugs.